288 related articles for article (PubMed ID: 35443675)
1. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Arthritis Res Ther; 2022 Apr; 24(1):88. PubMed ID: 35443675
[TBL] [Abstract][Full Text] [Related]
2. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.
Uhlig T; Eskild T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Dalbeth N; Hammer HB
Rheumatology (Oxford); 2022 Apr; 61(SI):SI81-SI85. PubMed ID: 34247224
[TBL] [Abstract][Full Text] [Related]
3. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Stamp L; Horne A; Mihov B; Drake J; Haslett J; Chapman PT; Frampton C; Dalbeth N
Ann Rheum Dis; 2023 Dec; 82(12):1626-1634. PubMed ID: 37652661
[TBL] [Abstract][Full Text] [Related]
4. Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.
Maher D; Reeve E; Hopkins A; Tan JM; Tantiongco M; Ailabouni N; Woodman R; Stamp L; Bursill D; Proudman S; Wiese M
Arthritis Care Res (Hoboken); 2024 Jun; 76(6):871-881. PubMed ID: 38303574
[TBL] [Abstract][Full Text] [Related]
5. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Clin Rheumatol; 2022 Dec; 41(12):3817-3823. PubMed ID: 36316609
[TBL] [Abstract][Full Text] [Related]
6. Cohort study investigating gout flares and management in UK general practice.
Finnikin S; Mallen CD; Roddy E
BMC Prim Care; 2023 Nov; 24(1):246. PubMed ID: 37993770
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation: a prospective cohort study.
Hu S; Sun M; Li M; Xue X; Terkeltaub R; Wang C; Wang M; Lu J; Ran Z; Li H; Ji A; Sun W; Li X; He Y; Liu Z; Zhang H; Wang X; Ji X; Dalbeth N; Li C
Rheumatology (Oxford); 2023 Jul; 62(7):2435-2443. PubMed ID: 36409036
[TBL] [Abstract][Full Text] [Related]
9. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
10. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare.
Tai V; Gow P; Stewart S; Satpanich P; Li C; Abhishek A; Dalbeth N
Semin Arthritis Rheum; 2024 Apr; 65():152367. PubMed ID: 38215627
[TBL] [Abstract][Full Text] [Related]
11. Gout, flares, and allopurinol use: a population-based study.
Proudman C; Lester SE; Gonzalez-Chica DA; Gill TK; Dalbeth N; Hill CL
Arthritis Res Ther; 2019 May; 21(1):132. PubMed ID: 31151457
[TBL] [Abstract][Full Text] [Related]
12. Palpable tophi and more comorbidities associated with adherence to urate-lowering medical therapy in a Chinese gout cohort.
Hu S; Terkeltaub R; Sun M; Ji X; Li Z; Ran Z; Li Y; Zhang H; Sun W; Li C; Lu J
Joint Bone Spine; 2022 Nov; 89(6):105435. PubMed ID: 35777552
[TBL] [Abstract][Full Text] [Related]
13. Latent Class Growth Analysis of Gout Flare Trajectories: A Three-Year Prospective Cohort Study in Primary Care.
Watson L; Belcher J; Nicholls E; Muller S; Mallen C; Roddy E
Arthritis Rheumatol; 2020 Nov; 72(11):1928-1935. PubMed ID: 32767502
[TBL] [Abstract][Full Text] [Related]
14. [Gout management: an update].
Ankli B; Krähenbühl S
Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
[TBL] [Abstract][Full Text] [Related]
15. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.
Uhlig T; Karoliussen LF; Sexton J; Borgen T; Haavardsholm EA; Kvien TK; Hammer HB
RMD Open; 2021 Mar; 7(1):. PubMed ID: 33782189
[TBL] [Abstract][Full Text] [Related]
16. UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis.
Ebstein E; Forien M; Norkuviene E; Richette P; Mouterde G; Daien C; Ea HK; Brière C; Lioté F; Petraitis M; Bardin T; Ora J; Dieudé P; Ottaviani S
Joint Bone Spine; 2020 Dec; 87(6):647-651. PubMed ID: 32979555
[TBL] [Abstract][Full Text] [Related]
17. Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares.
Choi HJ; Lee CH; Lee JH; Yoon BY; Kim HA; Suh CH; Choi ST; Song JS; Joo HY; Choi SJ; Lee JS; Shin KC; Baek HJ
Int J Rheum Dis; 2017 Apr; 20(4):497-503. PubMed ID: 25160939
[TBL] [Abstract][Full Text] [Related]
18. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
19. Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
Peeters IR; den Broeder AA; Taylor WJ; den Broeder N; Flendrie M; van Herwaarden N
Trials; 2023 Apr; 24(1):282. PubMed ID: 37072799
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
Coleman GB; Dalbeth N; Frampton C; Haslett J; Drake J; Su I; Horne AM; Stamp LK
J Rheumatol; 2022 Dec; 49(12):1372-1378. PubMed ID: 35777814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
